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ABSTRACT Azithromycin resistance (AZM-R) of Neisseria gonorrhoeae is emerging as
a clinical and public health challenge. We determined molecular characteristics of re-
cent AZM-R Nanjing gonococcal isolates and tracked the emergence of AZM-R iso-
lates in eastern Chinese cities in recent years. A total of 384 N. gonorrhoeae isolates
from Nanjing collected from 2013 to 2014 were tested for susceptibility to AZM and
six additional antibiotics; all AZM-R strains were characterized genetically for resis-
tance determinants by sequencing and were genotyped using N. gonorrhoeae multi-
antigen sequence typing (NG-MAST). Among the 384 isolates, 124 (32.3%) were
AZM-R. High-level resistance (MIC, 256 mg/liter) was present in 10.4% (40/384) of
isolates, all of which possessed the A2143G mutation in all four 23S rRNA alleles.
Low- to mid-level resistance (MIC, 1 to 64 mg/liter) was present in 21.9% (84/384) of
isolates, 59.5% of which possessed the C2599T mutation in all four 23S rRNA alleles.
The 124 AZM-R isolates were distributed in 71 different NG-MAST sequence types
(STs). ST1866 was the most prevalent type in high-level AZM-R (HL-AZM-R) isolates
(45% [18/40]). This study, together with previous reports, revealed that the preva-
lence of AZM-R in N. gonorrhoeae isolates in certain eastern Chinese cities has risen
4-fold (7% to 32%) from 2008 to 2014. The principal mechanisms of AZM resis-
tance in recent Nanjing isolates were A2143G mutations (high-level resistance) and
C2599T mutations (low- to mid-level resistance) in the 23S rRNA alleles. Characteriza-
tion of NG-MAST STs and phylogenetic analysis indicated the genetic diversity of N.
gonorrhoeae in Nanjing; however, ST1866 was the dominant genotype associated
with HL-AZM-R isolates.
KEYWORDS Neisseria gonorrhoeae, azithromycin, antimicrobial resistance, molecular
epidemiology, eastern Chinese cities
Gonorrhea is the second most prevalent sexually transmitted bacterial infection inthe world. In 2012, the WHO estimated that the number of new cases of gono-
coccal infection worldwide was 78.3 million per year (1). In 2016, the Chinese Centers
for Disease Control and Prevention reported 115,024 cases; gonorrhea ranked ﬁfth
among reported infectious diseases in China (2).
Antimicrobial resistance (AMR) of Neisseria gonorrhoeae is a major public health
problem worldwide. N. gonorrhoeae has developed AMR to most antimicrobial agents
previously recommended for treatment (3). The emergence of decreased susceptibility
or frank resistance of N. gonorrhoeae to ceftriaxone (3–5) (the last available agent used
for ﬁrst-line empirical monotherapy) has resulted in public health recommendations
from Australia, Canada, Europe and the United States to use dual antimicrobial therapy
consisting of a single dose of ceftriaxone (250 mg or 500 mg intramuscularly) and
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azithromycin (AZM) (1 g or 2 g orally) together (6–9). In addition to treating gonorrhea
alone, AZM is also used to treat presumptive coinfection with Chlamydia trachomatis (6,
10, 11), thereby achieving de facto dual therapy for gonococcal infection. Incremental
increases in gonococcal MICs of AZM have been reported from several continents
(12–14). The sporadic development of high-level AZM resistance (HL-AZM-R) (15–22)
and numerous clinical failures (23–27) in many countries are of great concern and
threaten the long-term efﬁcacy of the currently recommended regimen.
AZM exerts its antimicrobial effect by binding to the 23S rRNA component of the
50S ribosome and inhibits protein synthesis by preventing the elongation of peptide
chains. AZM resistance (AZM-R) in N. gonorrhoeae results from point mutations in 23S
rRNA alleles of the rrl gene that include A2143G (numbering corresponds to A2059 in
Escherichia coli) or C2599T (numbering corresponds to C2611T in E. coli) and the
overexpression of the MtrCDE efﬂux pump caused by mutations either in the coding
region of the mtrR gene or in the mtrR promoter (28–31). In addition, mutations in the
ribosomal genes rplD (encoding ribosomal protein L4) and rplV (encoding ribosomal
protein L22), as described for E. coli and Streptococcus pneumoniae, may confer resis-
tance to macrolides due to a change in the conformation of 23S rRNA domains (32);
however, this mutation is unusual in N. gonorrhoeae (3).
China developed a national surveillance system to monitor N. gonorrhoeae AMR in
1987 and then joined the WHO Western Paciﬁc Regional Gonococcal Antimicrobial
Susceptibility Programme in 1992. However, AZM resistance had not been monitored
at the national level in China before 2013. Consequently, AZM resistance and molecular
characterization of AZM-R N. gonorrhoeae in China had been limited (22, 33–35).
Between 2013 and 2016, the China Gonococcal Resistance Surveillance Programme
(China-GRSP) determined that the prevalence of gonococcal AZM-R was 18.6% nation-
ally (3,849 isolates tested from 7 sentinel sites located throughout China) (36). In the
absence of new antimicrobials available for the treatment of gonorrhea, classiﬁcation of
the emergence and dynamics of AZM-R N. gonorrhoeae strains on a regional and
national basis is important in order to update treatment recommendations successfully.
Accordingly, since 2013, AZM has been added to antimicrobial susceptibility panels to
test N. gonorrhoeae susceptibility in Nanjing, China. Here we report the prevalence of
AZM-R N. gonorrhoeae and the genetic characteristics of AZM-R isolates isolated in
Nanjing from January 2013 to December 2014, and we track chronologically the
emergence of AZM-R N. gonorrhoeae isolates in eastern Chinese cities over the past
several years.
RESULTS
Subject characteristics. Among 905 consecutively enrolled male subjects with
urethritis, 392 (43.3%) were infected with N. gonorrhoeae in the 2-year period 2013–
2014. The mean age was 38.1 years (range, 18 to 71 years); 98.9% (388/392) were ethnic
Han, and 69.6% (273/392) were married but indicated that they had had extramarital
sex (an enrollment requirement in a separate study to examine the transmission of
gonorrhea from men to women). All male subjects reported that they were heterosex-
ual. Thirty-nine percent (153/392) reported that they had taken antibiotics in the 30
days prior to their clinic visit.
Antimicrobial susceptibility testing. Of 392 isolates, 384 (98%) were recovered
from storage. The MIC distribution of azithromycin for all isolates is shown in Fig. 1. The
MICs of azithromycin ranged from 0.015 to 2,048 mg/liter, with a MIC50 and MIC90
of 0.5 and 2,048 mg/liter, respectively (Fig. 1). Of the 384 isolates, 124 (32.3%)
displayed AZM-R, including 21.9% (84/384) with low- to mid-level resistance (MIC, 1 to
64 mg/liter) and 10.4% (40/384) that were highly resistant (deﬁned as a MIC of 256
mg/liter but actually 2,048 mg/liter). Compared with that in 2008–2009, the preva-
lence of AZM-R isolates (6.8% [16/236]) (33) had increased signiﬁcantly (P  0.001) in
the 5 intervening years. All AZM-R isolates were susceptible to spectinomycin and
ceﬁxime; however, coresistance to ciproﬂoxacin, tetracycline, and penicillin was also
observed (100%, 91.1%, and 83.9%, respectively) (Table 1). In addition, 20 low- to
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mid-level AZM-R (MIC, 1 to 64 mg/liter) isolates also manifested decreased susceptibility
to ceftriaxone (CRO-DS), similar to that reported for an isolate from a patient with a
pharyngeal infection, who had become infected in Japan and failed treatment with
ceftriaxone and azithromycin (37).
Determinants of resistance to azithromycin. The AMZ-R mutation A2143G was
found in the four alleles of the 23S rRNA gene in all HL-AZM-R isolates (n 40) but was
absent in all low- to mid-level AZM-R isolates (n  84) (Tables 2 and 3). The C2599T
mutation was present in the four 23S rRNA gene alleles in 59.5% (50/84) of isolates with
low- to mid-level AZM-R but was absent from the 40 HL-AZM-R isolates (Tables 2 and 3).
Examination of the mtrR promoter region showed that the prevalence of a single
nucleotide deletion (A) in the 13-bp inverted-repeat sequence was no different in
HL-AZM-R isolates (90% [36/40]) from that in low- to mid-level AZM-R isolates (83.3%
[70/84]) (P 0.05) (Tables 2 and 3). In contrast, the percentage (and number) of isolates
with the G45D mutation in the mtrR-coding region was signiﬁcantly higher among
HL-AZM-R isolates (70% [28/40]) than among low- to mid-level AZM-R isolates (13.1%
[11/84]) (P  0.001). Signiﬁcantly more low- to mid-level AZM-R isolates (71.4% [60/84])
than HL-AZM-R isolates (22.5% [9/40]) exhibited the H105Y mutation in mtrR-coding
regions (P  0.001). The prevalence of the A39T mutation did not differ between
HL-AZM-R (2.5% [1/40]) and low- to mid-level AZM-R (4.7% [4/84]) isolates (Tables 2 and
3). Eighteen of 40 HL-AZM-R isolates were represented by a single N. gonorrhoeae
multiantigen sequence typing (NG-MAST) type, ST1866 (see below). The prevalence of
the G45D mutation was higher in the 18 ST1866 isolates (94.4% [17/18]) than in the
remaining 22 HL-AZM-R isolates (50% [11/22]) (P  0.05); the H105Y mutation was
present in 41% (9/22) of the remaining 22 HL-AZM-R isolates but was absent from the
18 ST1866 isolates (P  0.05). No isolates contained double mutations: A39T H105Y or
G45D H105Y in the mtrR coding region. Point mutations in the rplD or rplV genes were
not detected in any of the isolates tested.
FIG 1 Distributions of MICs for AZM-R N. gonorrhoeae isolates in Nanjing from 2013 to 2014 (n 
384).
TABLE 1 Coresistance to ciproﬂoxacin, tetracycline, penicillin, spectinomycin, ceftriaxone,
and ceﬁxime among AZM-R N. gonorrhoeae isolates
Antimicrobial resistancea
No. (%) of AZM-R N. gonorrhoeae
isolates (n  124)
CIP-R 124 (100)
TET-R 113 (91.1)
PEN-R 104 (83.9)
SPT-R 0
CRO-DS 20 (16.1)b
CFM-DS 0
aCIP-R, TET-R, PEN-R, and SPT-R, resistance to ciproﬂoxacin, tetracycline, penicillin, and spectinomycin,
respectively (MICs, 1, 2, 2, and 128 mg/liter, respectively). CRO-DS, and CFM-DS, decreased
susceptibility to ceftriaxone and ceﬁxime, respectively (MICs, 0.125 and 0.25 mg/liter, respectively).
bAll 20 isolates exhibited low- to mid-level AZM-R.
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Molecular epidemiologic typing. As determined by NG-MAST analysis, 71 different
sequence types (STs) were represented in the 124 AZM-R isolates; 53/71 STs (74.6%)
were represented once in single isolates (Table 2). Twenty-eight of the 71 STs repre-
sented (39.4%) have not been reported previously in the NG-MAST database. ST1866
predominated among the HL-AZM-R isolates (18/40 [45.0%]), followed by ST5309 (5
isolates), ST5061 (4 isolates), and ST11929 (2 isolates); 11 HL-AZM-R isolates each
possessed a different ST. Among low- to mid-level AZM-R isolates, ST3356 (7 isolates)
was the most prevalent ST, followed by ST270 (5 isolates), ST436 (5 isolates), ST11931
(4 isolates), and ST4007 (3 isolates); 9 different STs were represented in 9 pairs of low-
to mid-level AZM-R isolates (9 groups of 2); 42 isolates each possessed a different ST.
Three large clusters (10 isolates) (boxed in Fig. 2) were identiﬁed based on
phylogenetic analysis. Cluster A isolates were represented by 8 different STs with the
same tbpB 186, except for ST5309 (tbpB 479); tbpB 186 and 479 differ by a single base
pair only. Cluster B isolates were represented by 6 different STs; all were low- to
mid-level AZM-R isolates and possessed the C2599T mutation in all four 23S rRNA gene
alleles. Cluster C isolates were represented by 5 different STs. Notably, 4/5 STs (ST1866,
ST11907, ST11911, and ST11941) in cluster C exhibited HL-AZM-R and possessed tbpB
33; each isolate contained the A2143G mutation in all four 23S rRNA gene alleles. The
remaining ST in cluster C, ST11922, was associated with low- to mid-level AZM-R
isolates possessing tbpB 215; tbpB 33 and 215 differ only by a single base pair. All 18
TABLE 2MICs, molecular resistance determinants, and NG-MAST types in 124 AZM-R N. gonorrhoeae isolates, Nanjing, 2013 to 2014
Azithromycin MIC
(mg/liter) (no. of
isolates)
23S rRNA mutation (no. of
mutated alleles; no. of
isolates) mtrR mutation (no. of isolates) NG-MAST ST (no. of isolates)
1–64 (84) 2599T (4; 50) A-deletion in the mtrR promotera (70),
mtrR A39T (4), mtrR G45D (11), mtrR
H105Y (60)
3356 (7), 270 (5), 436 (5), 11931b (4),
4007 (3), 568 (2), 1055 (2), 2318
(2), 11133 (2), 11890 (2), 11921b
(2), 11930b (2), 11932b (2), 11955b
(2), single STs (42)
256 (40) A2143G (4; 40) A-deletion in the mtrR promoter (36),
mtrR A39T (1), mtrR G45D (28), mtrR
H105Y (9)
1866 (18), 5309 (5), 5061 (4), 11929b
(2), single STs (11)
aA single nucleotide deletion (A) in the 13-bp inverted-repeat sequence of the mtrR promoter.
bNew NG-MAST ST identiﬁed in this study.
TABLE 3 Comparison of gene mutations in low- to mid-level AZM-R versus HL-AZM-R
N. gonorrhoeae isolates (n  124)
Gene and presence or absence
of resistance determinant(s)
No. (%) of N. gonorrhoeae isolates
P valuea
Low- to mid-level
AZM-R (n  84)
HL-AZM-R
(n  40)
23S rRNA
A2143G (all 4 alleles) 0 40 (100) 0.001
No A2143G 84 (100) 0
C2599T (all 4 alleles) 50 (59.5) 0 0.001
No C2599T 34 (40.5) 40
mtrR
A-deletion in the promoterb
A-deletion 70 (83.3) 36 (90.0) 0.325
No A-deletion 14 (16.7) 4 (10.0)
Mutations in the coding region
A39T 4 (4.7) 1 (2.5) 0.404
No A39T 80 (95.3) 39 (97.5)
G45D 11 (13.1) 28 (70.0) 0.001
No G45D 73 (86.9) 12 (30.0)
H105Y 60 (71.4) 9 (22.5) 0.001
No H105Y 24 (28.6) 31 (77.5)
aDetermined by the 2 or Fisher exact test.
bA single nucleotide deletion (A) in the 13-bp inverted-repeat sequence of the mtrR promoter.
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FIG 2 Phylogenetic tree constructed using MEGA7 with the concatenated sequences of porB and tbpB
alleles for NG-MAST STs of 124 AZM-R N. gonorrhoeae isolates from Nanjing, China, 2013 to 2014. ST1866
is indicated by a red asterisk; non-ST1866, HL-AZM-R STs are indicated by green asterisks.
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NG-MAST ST1866 isolates exhibited HL-AZM-R and were represented by two multilocus
sequence types (MLSTs), MLST 10899 (n 13) and MLST 12039 (n 5). MLST 10899 and
MLST 12039 share identical sequences in six of the seven housekeeping genes and
contain only a single (different) SNP (single nucleotide polymorphism) in the pdh gene,
which likely reﬂects ongoing evolution of the same strain. However, the remaining 22
HL-AZM-R isolates were widely distributed in the phylogenetic tree and did not belong
to any single major cluster (Fig. 2).
Prevalence of AZM-R N. gonorrhoeae in eastern Chinese cities. Four eastern/
southeastern Chinese cities have reported AZM-R N. gonorrhoeae isolates between
2008 and 2015, and the prevalence of resistance has risen steadily (Fig. 3). In Nanjing
(2008–2009), the prevalence of AZM-R N. gonorrhoeae was 6.8% (16/236) (33); in
Hangzhou (2011–2012), resistance and high-level resistance to azithromycin were 21%
(25/118) and 18% (21/118), respectively (22); in Guangzhou (2009–2013), resistance was
15.9% (77/485) (34); and in Hefei, resistance and high-level resistance to azithromycin
were 28.6% (36/126) and 10% (13/126) in 2014 and 2015, respectively (35).
DISCUSSION
AZM is widely used in China to treat C. trachomatis infection, but it is not recom-
mended for use as monotherapy to treat gonorrhea. Instead, AZM is used in combi-
nation with primary antigonococcal therapy to treat coinfection with Chlamydia (11).
Our results indicate that the prevalence of AZM-R N. gonorrhoeae in Nanjing has risen
4-fold, from 6.8% to 32.3%, in the 7-year period between 2008 and 2009 (33) to
2013–2014, exceeding the national average by 1 3/4-fold in the latter period (36).
During an earlier and overlapping period between 2009 and 2015, AZM-R almost
doubled in three other eastern (and southeastern) Chinese cities, progressing from 16%
in Guangzhou (2009–2013) (34) to 21% in Hangzhou (2011–2012) (22) to 29% in Hefei
(2014–2015) (35) (Fig. 3). However, contemporary reports indicate that AZM-R gono-
coccal infection outside China has remained low, e.g., 7.9% of isolates (163/2,069) in
Europe in 2014 (12), 2.5% (127/5,093) in the United States in 2014 (13), and 1.5%
(26/1,781) in South America in 2010 to 2011 (14).
Importantly, 18% of N. gonorrhoeae isolates in Hangzhou (22), 10% of isolates in
Hefei (35), and 10.4% of isolates in the present Nanjing study exhibited high-level
azithromycin resistance (HL-AZM-R), in contrast to the situation in Guangzhou, where
between 2009 and 2013, HL-AZM-R was not detected (34). HL-AZM-R isolates have
been documented in several countries, but most cases have been sporadic (15–21). In
addition, our results show high coresistance to ciproﬂoxacin, tetracycline, and penicillin,
FIG 3 Geographic distribution and chronological emergence of reported AZM-R N. gonorrhoeae isolates
in four Chinese cities. On the map, eastern China is shown in blue; southeastern China, in light green.
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ﬁndings that coincide with other reports (22, 38). Although HL-AZM resistance was not
associated with gonococcal isolates that exhibited CRO-DS, the occurrence of 20 low-
to mid-level AZM-R isolates with CRO-DS may threaten the effective use of dual
antimicrobial treatment of gonorrhea, as evidenced by the reported failure to clear a
gonococcal infection caused by an isolate with CRO-DS and low- to mid-level azithro-
mycin resistance (37).
There are few studies that correlate clinical treatment failures with MICs for organ-
isms that have failed treatment when AZM has been used as single therapy for
gonorrhea; such reports rely on observations from clinical trials and case reports of
treatment failures (39). One study (26), suggested that the MIC breakpoint associated
with clinical treatment failures “appeared” to be 1 mg/liter when a 2-g dose of
azithromycin was used alone to treat gonococcal urethritis in men, as evidenced by
microbiologic cure in patients whose infecting strain had an AZM MIC of0.25 mg/liter
and microbiologic failure in 5 of 12 patients whose strain had a MIC of 1 mg/liter. A MIC
of 1 mg/liter coincides with the azithromycin breakpoint for N. gonorrhoeae established
by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (40). In
our study, 32.3% of isolates had an AZM MIC of 1 mg/liter. Azithromycin was
introduced into clinical practice in China in 1995 and has been widely used for
respiratory, urogenital, dermatologic, and other infections. In China, azithromycin
resistance has also been recognized in Treponema pallidum (41), Mycoplasma pneu-
moniae (42), Streptococcus pyogenes (43), and Mycoplasma genitalium (unpublished
data). Ceﬁxime has not been used for the treatment of gonorrhea in China, which may
explain why all azithromycin-resistant isolates in our study were fully susceptible to
ceﬁxime. All strains were susceptible to spectinomycin, which is used widely in China
for the treatment of gonorrhea. Spectinomycin MIC50 (16 mg/liter) and MIC90 (32
mg/liter) have remained unchanged for 10 years at the Nanjing STD clinic, and together
with AZM for the treatment of C. trachomatis, spectinomycin may represent a second
option for the treatment of gonorrhea in China (44, 45).
AZM exerts its bacteriostatic effect by interacting directly with the central loop of
domain V of the rrl gene encoding the 23S rRNA, which results in blockage of protein
synthesis. Speciﬁc point mutations that occur in this region likely lead to resistance by
reducing the afﬁnity of azithromycin for its target (28, 29). HL-AZM-R isolates harbor
mutation A2143G in at least three of the four alleles (15–22); in our study, the A2143G
mutation was present in all four alleles of HL-AZM-R N. gonorrhoeae. However, the
A2143G mutation was absent in all of the low- to mid-level AZM-R isolates. The C2599T
mutation, when present in two or more alleles, has been associated with low- to
mid-level AZM-R isolates (21, 31, 38); in our study, 59.5% (50/84) of low- to mid-level
AZM-R isolates possessed the C2599T mutation in all four alleles. Taken together,
current studies (including ours) suggest that A2143G or C2599T mutations in the 23S
rRNA alleles play a signiﬁcant role in the mechanism of AZM resistance in gonococci
(15–22, 34, 38).
Mutations in the promoter or coding sequence of the mtrR gene that are present in
macrolide-resistant gonococcal strains can result in decreased expression of the MtrR
repressor and consequent upregulation of the MtrCDE efﬂux pump (30, 31). In gono-
coccal strains with the A-deletion in the 13-bp inverted-repeat sequence of the mtrR
promoter (which overlaps the mtrCDE promoter at the 35 region), mtrR expression is
abrogated while mtrCDE expression is elevated, most likely because of the greater
binding afﬁnity of RNA polymerase for mtrCDE (46). A report of 59 gonococcal isolates
from Japan indicated that the A-deletion in the mtrR promoter was signiﬁcantly
associated with MICs of 0.5 mg/liter (47), a ﬁnding similar to that in our study, where
80% of both HL-AZM-R and low- to mid-level AZM-R isolates possessed this
A-deletion. Missense mutations in the mtrR gene that result in, for example, a G45D
mutation in the helix-turn-helix motif (located at amino acid [aa] 32 to aa 53) in the
MtrR repressor can diminish the binding of the repressor to the mtrCDE promoter (48,
49). In our study, the G45D mutation was present more often in HL-AZM-R isolates than
in low- to mid-level AZM-R isolates (P  0.001), a ﬁnding that coincides with previous
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ﬁndings (15, 22). The H105Y mutation in the MtrR repressor may inhibit MtrR dimeriza-
tion and reduce binding to DNA (50). We showed that the H105Y mutation was more
often present in low- to mid-level AZM-R isolates (P  0.001), indicating that H105Y
mutation could be implicated in the mechanism of low- to mid-level AZM resistance in
N. gonorrhoeae. No point mutations were seen in the rplD or rplV genes, in agreement
with another report (38).
NG-MAST analysis can be used to facilitate the tracking of antimicrobial-resistant
strains. Chinese studies continue to identify new and diverse NG-MAST types (22,
33–35). In our study, 28/124 (22.6%) types were newly recognized; overall, 53/124
(42.7%) NG-MAST types were represented by single isolates. Eighteen of 40 HL-AZM-R
isolates were represented by ST1866; the presence of the G45D and the H105Y
mutations each differed signiﬁcantly between the 18 ST1866 isolates and the 22
remaining HL-AZM-R isolates. Furthermore, phylogenetic analysis showed that the
remaining 22/40 HL-AZM-R isolates were widely divergent and did not belong to any
one of the major clusters, indicating high genetic variability of AMZ-R N. gonorrhoeae
in more than half of the Nanjing isolates. As in Guangzhou (34), this may be related to
large numbers of temporary residents in Nanjing, which results in a greater opportunity
to import foreign (or new) NG-MAST STs. Because of the widespread use of azithro-
mycin in China to treat patients with gonorrhea who are coinfected with C. trachomatis
(and other bacteria) (33), we cannot exclude the possibility that antibiotic pressure and
selection contributed to the diversity of NG-MAST types. With the exception of ST5309,
which has also been reported from Australia (20), other NG-MAST STs represented in
HL-AZM-R isolates in our study have not been reported in HL-AZM-R isolates from
countries such as Argentina, which has reported ST696 (15), Scotland, reporting ST470
and ST649 (16), England, Wales, and the United States, reporting ST649 (19, 21), Ireland,
reporting ST649 and ST3311 (17), Sweden, reporting ST285, ST332, and ST8727 (18),
and Australia, reporting ST649, ST8917, ST10133, and ST10572 (20), suggesting that
domestic sexual networks in Nanjing are not strongly linked to sexual networks abroad.
NG-MAST ST1866 was the predominant ST (18/40 [45.0%]) among Nanjing HL-AZM-R
isolates and was previously found in two AZM-R (MIC, 64 mg/liter) isolates in Nanjing
in 2008–2009 (33) and, more recently, in six HL-AZM-R isolates from Hangzhou and 5
AZM-R isolates from Hefei, both eastern Chinese cities (22, 35). The 18 NG-MAST ST1866
HL-AZM-R isolates in our study had almost the identical MLST type (MLST 10899 and
MLST 12039 differ only by one SNP in the pdh gene); a single MLST 10899 isolate was
identiﬁed among 5 HL-AZM-R isolates in a report from Canada (51). Our study suggests
that NG-MAST ST1866 isolates showing high-level azithromycin resistance may have
been spreading in eastern China for many years.
In conclusion, a high prevalence of azithromycin resistance has emerged among N.
gonorrhoeae isolates in Nanjing and other cities in eastern China. The A2143G mutation
present in all four alleles of the 23S rRNA was associated with high-level azithromycin
resistance (MIC, 2,048 mg/liter) and was identiﬁed in 10.4% (40/384) of Nanjing
isolates of N. gonorrhoeae. The C2599T mutation present in all four alleles of the 23S
rRNA was associated with low- to mid-level azithromycin resistance (MIC, 1 to 64
mg/liter) and was identiﬁed in 21.9% (84/384) of Nanjing isolates. NG-MAST and
analysis of a phylogenetic tree revealed that two types of genetic signatures represent
AZM-R strains in Nanjing: one is highly conserved among HL-AZM-R isolates (NG-MAST
ST1866, representing 45% of HL-AZM-R isolates), and the other is highly diverse. These
genotypes differ from those representing AZM-R strains in other parts of the world.
Because 16.1% (20/124) of AMZ-R Nanjing isolates also manifest CRO-DS, the use of
these two agents together for the treatment of gonorrhea in China, and indeed in other
parts of the world, may become problematic.
MATERIALS AND METHODS
Gonococcal isolates and susceptibility testing. Clinical gonococcal isolates were collected con-
secutively, between January 2013 and December 2014, from male adults with symptomatic urethritis
(urethral discharge and/or dysuria) attending the sexually transmitted disease (STD) clinic at the National
Center for STD Control in Nanjing, China. Isolates were cultured, identiﬁed, and preserved as described
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previously (52). MICs (mg/liter) of seven antibiotics (azithromycin, penicillin, tetracycline, ciproﬂoxacin,
spectinomycin, ceﬁxime, and ceftriaxone) were determined by the agar dilution method, according to
the Clinical and Laboratory Standards Institute (CLSI) guidelines (53). For quality control, N. gonorrhoeae
ATCC 49226, WHO reference strains A, G, J, K, O, P, and F, and a ceftriaxone-resistant strain (54) were
included each time susceptibility testing was performed. AZM resistance was deﬁned as a MIC of 1
mg/liter according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guide-
lines (www.eucast.org) (40); susceptibility to other antibiotics was determined according to CLSI stan-
dards (53). Decreased susceptibility to ceftriaxone (CRO-DS) (MIC, 0.125 mg/liter) and to ceﬁxime (MIC,
0.25 mg/liter) was deﬁned by the WHO in 2012 (55). AZM-R N. gonorrhoeae isolates (MIC, 1 mg/liter)
was divided into low- to mid-level (MIC, 1 to 64 mg/liter) and high-level (MIC, 256 mg/liter) resistance
in accordance with previous studies (22, 34).
Genetic determinants associated with resistance to azithromycin. Genomic DNA was extracted
using the DNA QuickExtract kit (Epicentre, USA) and was stored at 20°C. Primers and conditions used
for PCR have been published previously (56, 57). All four alleles in the peptidyltransferase loop of domain
V of the rrl gene encoding 23S rRNA were ampliﬁed using a two-step PCR and were sequenced as
described previously (56). The mtrR gene and its promoter were also ampliﬁed by PCR and sequenced
(57). PCR products were sequenced twice in both directions using an Applied Biosystems 3730xl DNA
automatic sequencer. The nucleotide and deduced amino acid sequences were analyzed using the
EditSeq program (LaserGene software [version 7.1; DNAStar Corp.]) and were aligned against their
respective prototypes using the Megalign program (LaserGene software). To identify mutations, DNA
sequences in the rrl, mtrR, rplV, and rplD genes were compared with corresponding sequences in N.
gonorrhoeae reference strain FA1090 (GenBank accession no. AE004969.1), which is an antimicrobial-
susceptible strain (pansensitive).
Molecular epidemiologic typing. Molecular epidemiologic analysis was performed on all AZM-R N.
gonorrhoeae isolates by N. gonorrhoeae multiantigen sequence typing (NG-MAST), which assigns se-
quence types (STs) based on a combination of two hypervariable porB and tbpB alleles (58). Allele
numbers and STs were assigned using the NG-MAST database (http://www.ng-mast.net). A maximum-
likelihood phylogenetic tree was created using MEGA7 (http://www.megasoftware.net/download-form)
(59) using concatenated porB and tbpB alleles. Eighteen NG-MAST ST1866 isolates with high-level AZM
resistance were further typed using multilocus sequence typing (MLST) (60), which analyzes seven
housekeeping genes (abcZ, adk, aroE, fumC, gdh, pdh, and pgm) (http://pubmlst.org/neisseria/).
Review of AZM-R N. gonorrhoeae in eastern Chinese cities. A Medline search was conducted using
PubMed under the major headings of “Neisseria gonorrhoeae,” “azithromycin,” “China,”’ and “antimicro-
bial resistance.”
Statistical analysis. A total of 124 AZM-R isolates were included in the statistical analysis. Chi-square
(2) testing or the Fisher exact test was used to compare the number of isolates with resistance mutations
in low- to mid-level AZM-R isolates with the number of high-level AZM-R (HL-AZM-R) isolates with
mutations. IBM SPSS Statistics, version 19.0, was used for statistical analysis; a P value of 0.05 was
considered statistically signiﬁcant.
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